Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
J Am Geriatr Soc. 2011 Sep;59(9):1705-10. doi: 10.1111/j.1532-5415.2011.03539.x. Epub 2011 Aug 24.
To examine the influence of age on the value of four techniques for diagnosing Alzheimer's disease (AD).
Observational cohort study.
Alzheimer's Disease Neuroimaging Initiative.
Individuals with mild cognitive impairment (MCI; n = 179), individuals with AD (n = 91), and normal controls (n = 105).
Neuropsychological tests, structural magnetic resonance imaging (MRI), amyloid-beta and tau in cerebrospinal fluid (CSF), and [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) for the diagnosis of MCI or AD. MCI was defined according to subjective memory complaints corroborated by an informant and an abnormal score on the delayed paragraph recall subtest of the Wechsler Memory Scale-Revised, a Mini-Mental State Examination score greater than 23, and a Clinical Dementia Rating score of 0.5. Participants with AD satisfied National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria of probable AD.
Neuropsychological tests and MRI were the most informative techniques, with 84% and 82% correct classifications, respectively, and areas under the receiver operating characteristic curve (AUCs) of 0.93 (90% confidence interval (CI) = 0.91-0.95) and 0.88 (90% CI = 0.85-0.91). FDG-PET and CSF assessments had 76% and 73% correct classifications, respectively, (AUC = 0.77, 90% CI = 0.71-0.83; AUC = 0.77, 90% CI = 0.73-0.82). These figures increased slightly when the techniques were combined. All analyses were repeated for the younger (<75) and older (≥ 75) halves of the sample. FDG-PET and CSF assessment were substantially less informative in the older cohort, and they did not add diagnostic information when all techniques were combined.
Structural MRI and neuropsychological assessment are diagnostic methods of first choice if AD is suspected. CSF and FDG-PET add little to these diagnostic techniques, especially in older adults.
研究年龄对四种阿尔茨海默病(AD)诊断技术的价值的影响。
观察性队列研究。
阿尔茨海默病神经影像学倡议。
轻度认知障碍(MCI;n=179)、AD 患者(n=91)和正常对照(n=105)。
神经心理学测试、结构磁共振成像(MRI)、脑脊液(CSF)中的β-淀粉样蛋白和tau、[18F]氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)用于诊断 MCI 或 AD。MCI 根据主观记忆主诉并经知情人证实,韦氏记忆量表修订版延迟段回忆子测验异常,简易精神状态检查评分>23,临床痴呆评定量表评分为 0.5 定义。AD 患者符合国家神经病学、语言障碍和中风/阿尔茨海默病及相关疾病协会的可能 AD 标准。
神经心理学测试和 MRI 是最具信息性的技术,分别有 84%和 82%的正确分类,其受试者工作特征曲线下面积(AUC)分别为 0.93(90%置信区间(CI)=0.91-0.95)和 0.88(90%CI=0.85-0.91)。FDG-PET 和 CSF 评估的正确分类分别为 76%和 73%(AUC=0.77,90%CI=0.71-0.83;AUC=0.77,90%CI=0.73-0.82)。当这些技术结合使用时,这些数字略有增加。所有分析均在样本的年轻(<75 岁)和年长(≥75 岁)两半部分中重复进行。FDG-PET 和 CSF 评估在老年队列中信息量明显较少,当所有技术结合使用时,它们没有增加诊断信息。
如果怀疑 AD,结构 MRI 和神经心理学评估是首选的诊断方法。CSF 和 FDG-PET 对这些诊断技术的贡献不大,尤其是在老年人中。